ITCI RSI Chart
Last 7 days
13.9%
Last 30 days
17.3%
Last 90 days
17.7%
Trailing 12 Months
22.9%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 310.6M | 365.8M | 420.1M | 464.4M |
2022 | 102.9M | 138.5M | 188.1M | 250.3M |
2021 | 37.6M | 55.7M | 70.6M | 83.8M |
2020 | 9.3M | 13.8M | 18.3M | 22.8M |
2019 | 0 | 0 | 0 | 4.8M |
2017 | 426.0K | 312.3K | 338.7K | 245.8K |
2016 | 0 | 316.5K | 263.5K | 361.4K |
2015 | 0 | 466.9K | 247.7K | 153.9K |
2014 | 2.3M | 1.9M | 1.3M | 577.3K |
2013 | 3.1M | 2.3M | 2.6M | 2.7M |
2012 | 0 | 16.6M | 9.9M | 3.1M |
2011 | 0 | 0 | 0 | 23.4M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 31, 2024 | riggs rory b | acquired | 17,992 | 69.2 | 260 | - |
Mar 31, 2024 | van nostrand robert l | acquired | 5,466 | 69.2 | 79.00 | - |
Mar 20, 2024 | riggs rory b | acquired | 371,200 | 18.56 | 20,000 | - |
Mar 11, 2024 | hineline lawrence j. | sold | -667,587 | 65.9606 | -10,121 | svp of finance, cfo |
Mar 11, 2024 | mates sharon | sold | -1,341,120 | 65.2139 | -20,565 | chairman, president & ceo |
Mar 11, 2024 | neumann mark | sold | -481,931 | 65.6135 | -7,345 | evp, chief commercial officer |
Mar 11, 2024 | halstead michael | sold | -484,537 | 65.9683 | -7,345 | evp and general counsel |
Mar 11, 2024 | durgam suresh k. | sold | -243,482 | 65.5933 | -3,712 | evp, chief medical officer |
Mar 10, 2024 | halstead michael | acquired | - | - | 7,345 | evp and general counsel |
Mar 10, 2024 | durgam suresh k. | acquired | - | - | 7,345 | evp, chief medical officer |
Which funds bought or sold ITCI recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 15, 2024 | EXCHANGE TRADED CONCEPTS, LLC | new | - | 3,806 | 3,806 | -% |
Apr 15, 2024 | Legato Capital Management LLC | added | 27.89 | 193,495 | 1,014,400 | 0.12% |
Apr 15, 2024 | FRANKLIN STREET ADVISORS INC /NC | unchanged | - | -33,000 | 954,000 | 0.07% |
Apr 15, 2024 | PFS Partners, LLC | reduced | -41.41 | -15,910 | 20,760 | 0.01% |
Apr 15, 2024 | OLD NATIONAL BANCORP /IN/ | unchanged | - | -50,299 | 1,438,320 | 0.03% |
Apr 12, 2024 | DNB Asset Management AS | added | 548 | 3,881,620 | 4,619,310 | 0.02% |
Apr 12, 2024 | Financial Synergies Wealth Advisors, Inc. | unchanged | - | 98.00 | 416 | -% |
Apr 11, 2024 | Fortitude Family Office, LLC | unchanged | - | -179 | 5,121 | -% |
Apr 10, 2024 | PARK AVENUE SECURITIES LLC | reduced | -0.45 | -15,000 | 385,000 | -% |
Apr 10, 2024 | Banque Cantonale Vaudoise | added | 15.82 | 6,000 | 54,000 | -% |
Unveiling Intra-Cellular Therapies Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Date Filed | Form Type | Document | |
---|---|---|---|
Peers (Alternatives to Intra-Cellular Therapies Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 348.8B | 85.2B | 9.92 | 4.1 | ||||
MRK | 317.6B | 60.1B | 870.05 | 5.28 | ||||
PFE | 143.5B | 46.5B | -103.34 | 3.08 | ||||
AMGN | 141.5B | 28.2B | 21.07 | 5.02 | ||||
GILD | 83.4B | 27.1B | 14.73 | 3.08 | ||||
TEVA | 14.8B | 15.8B | -25.67 | 0.93 | ||||
MID-CAP | ||||||||
PRGO | 4.1B | 4.7B | -320.54 | 0.87 | ||||
ALKS | 4.0B | 1.7B | 11.28 | 2.41 | ||||
BHC | 3.2B | 8.8B | -5.35 | 0.36 | ||||
AMPH | 1.9B | 644.4M | 14 | 2.99 | ||||
SMALL-CAP | ||||||||
TLRY | 1.3B | 743.2M | -3.78 | 1.79 | ||||
TXMD | 21.8M | 1.3M | -2.12 | 16.74 | ||||
ACRX | 17.1M | - | -0.93 | 0.22 | ||||
AGRX | 2.5M | 19.6M | -0.18 | 0.13 | ||||
ACOR | 422.3K | 117.6M | 0 | 0 |
Intra-Cellular Therapies Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2017Q4 | 2017Q3 | 2017Q2 | 2017Q1 |
Revenue | 4.7% | 132,099,000 | 126,173,000 | 110,792,000 | 95,306,000 | 87,869,000 | 71,870,000 | 55,579,000 | 34,996,000 | 25,671,000 | 22,207,000 | 20,047,000 | 15,878,000 | 12,454,291 | 7,368,594 | 1,906,636 | 1,083,479 | 544,267 | 5,055 | 30,754 | 114,741 | 95,287 |
Operating Expenses | 6.6% | 166,196,000 | 155,886,000 | 157,971,000 | 143,698,000 | 135,281,000 | 127,499,000 | 143,502,000 | 107,658,000 | 111,675,000 | 99,531,000 | 89,188,000 | 69,097,000 | 73,787,606 | 63,305,048 | 66,778,953 | 50,169,003 | 41,829,272 | - | - | - | - |
S&GA Expenses | -0.5% | 104,720,000 | 105,207,000 | 101,014,000 | 98,923,000 | 94,631,000 | 88,375,000 | 100,316,000 | 75,460,000 | 79,678,000 | 70,498,000 | 69,851,000 | 52,584,000 | 58,348,504 | 52,473,573 | 41,445,557 | 34,096,366 | 22,763,547 | - | - | - | - |
R&D Expenses | 22.2% | 50,774,000 | 41,550,000 | 49,794,000 | 38,024,000 | 33,862,000 | 33,274,000 | 38,536,000 | 29,043,000 | 29,458,000 | 27,032,000 | 17,297,000 | 15,058,000 | 14,298,449 | 10,275,368 | 25,204,857 | 16,003,326 | 19,065,726 | - | - | - | - |
EBITDA Margin | 18.8% | -0.30 | -0.37 | -0.50 | -0.73 | -1.02 | -1.58 | -2.32 | -2.94 | -3.38 | -3.66 | -4.25 | -6.16 | - | - | - | - | - | - | - | - | - |
Income Taxes | 941.9% | 448,000 | 43,000 | 135,000 | 10,000 | - | 1,000 | - | 5,000 | 6,000 | 23,000 | -24,000 | -5,000 | -10,232 | - | - | -3,281 | - | -1,060,851 | - | - | - |
Earnings Before Taxes | -16.2% | -28,131,000 | -24,215,000 | -42,649,000 | -44,043,000 | -44,026,000 | -53,507,000 | -86,603,000 | -72,114,000 | -85,734,000 | -76,931,000 | -68,720,000 | -52,735,000 | -60,688,796 | -55,183,625 | -63,712,258 | -47,407,321 | -40,582,851 | - | - | - | - |
EBT Margin | 18.8% | -0.30 | -0.37 | -0.50 | -0.73 | -1.02 | -1.58 | -2.32 | -2.95 | -3.39 | -3.67 | -4.26 | -6.18 | - | - | - | - | - | - | - | - | - |
Net Income | -17.8% | -28,579,000 | -24,258,000 | -42,784,000 | -44,053,000 | -44,026,000 | -53,508,000 | -86,603,000 | -72,119,000 | -85,734,000 | -76,908,000 | -68,744,000 | -52,740,000 | -60,699,178 | -55,183,625 | -63,712,258 | -47,410,602 | -40,582,851 | - | - | - | - |
Net Income Margin | 18.5% | -0.30 | -0.37 | -0.50 | -0.73 | -1.02 | -1.58 | -2.32 | -2.95 | -3.39 | -3.67 | -4.26 | -6.18 | - | - | - | - | - | - | - | - | - |
Free Cashflow | 91.9% | -2,062,000 | -25,538,000 | -36,802,000 | -60,066,000 | -39,165,000 | -53,468,000 | -94,916,000 | -83,415,000 | -73,185,000 | -79,576,000 | -59,341,000 | -47,767,000 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | 1.5% | 728 | 718 | 714 | 722 | 755 | 782 | 812 | 869 | 490 | 557 | 626 | 674 | 717 | 771 | 441 | 481 | 251 | 281 | 310 | 343 | 357 |
Current Assets | -4.9% | 668 | 702 | 698 | 706 | 738 | 760 | 789 | 848 | 467 | 533 | 601 | 649 | 691 | 745 | 419 | 461 | 230 | 259 | 288 | 321 | 355 |
Cash Equivalents | 48.7% | 148 | 99.00 | 142 | 76.00 | 149 | 135 | 77.00 | 129 | 92.00 | 106 | 121 | 130 | 61.00 | 301 | 129 | 180 | 108 | 102 | 92.00 | 64.00 | 55.00 |
Inventory | -72.9% | 12.00 | 43.00 | 42.00 | 28.00 | 24.00 | 24.00 | 25.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 7.00 | 3.00 | 2.00 | 1.00 | - | - | - | - | - |
Net PPE | -7.5% | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 1.00 | 1.00 |
Liabilities | 17.0% | 137 | 117 | 107 | 95.00 | 99.00 | 97.00 | 90.00 | 76.00 | 72.00 | 70.00 | 72.00 | 62.00 | 60.00 | 62.00 | 61.00 | 51.00 | 56.00 | 54.00 | 53.00 | 54.00 | 39.00 |
Current Liabilities | 19.8% | 124 | 103 | 92.00 | 80.00 | 83.00 | 77.00 | 71.00 | 59.00 | 53.00 | 50.00 | 50.00 | 40.00 | 37.00 | 38.00 | 40.00 | 31.00 | 36.00 | 33.00 | 33.00 | 33.00 | 36.00 |
Shareholder's Equity | -1.5% | 591 | 601 | 607 | 628 | 656 | 685 | 722 | 793 | 418 | 487 | 554 | 612 | 657 | 709 | 380 | 430 | 195 | 227 | 257 | 289 | 318 |
Retained Earnings | -1.8% | -1,617 | -1,588 | -1,564 | -1,521 | -1,477 | -1,433 | -1,379 | -1,293 | -1,221 | -1,135 | -1,058 | -989 | -937 | -876 | -821 | -757 | -710 | -669 | -634 | -597 | -562 |
Additional Paid-In Capital | 0.8% | 2,208 | 2,191 | 2,174 | 2,152 | 2,138 | 2,124 | 2,107 | 2,089 | 1,639 | 1,622 | 1,612 | 1,602 | 1,593 | 1,585 | 1,200 | 1,188 | 905 | 896 | 891 | 886 | 881 |
Shares Outstanding | 0.2% | 96.00 | 96.00 | 96.00 | 96.00 | 95.00 | 94.00 | 94.00 | 93.00 | 81.00 | 81.00 | 81.00 | 81.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | 6,000 | - | - | - | - | - | - | - | 5,300 | - | - | - | 3,200 | - | - | - | 614 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | 91.8% | -2,061 | -25,270 | -36,802 | -60,066 | -39,193 | -53,351 | -94,793 | -82,849 | -73,184 | -79,267 | -59,326 | -47,767 | -68,242 | -63,579 | -47,024 | -51,226 | -35,055 | -29,989 | -27,308 | -35,629 | -29,161 |
Share Based Compensation | 3.8% | 14,856 | 14,311 | 13,226 | 10,439 | 11,159 | 11,751 | 11,998 | 8,105 | 9,378 | 9,530 | 8,617 | 6,778 | 4,763 | 6,901 | 6,947 | 5,504 | 5,939 | 4,807 | 4,987 | 5,055 | 4,425 |
Cashflow From Investing | 335.1% | 47,422 | -20,167 | 94,748 | -16,462 | 50,263 | 106,170 | 37,229 | -322,035 | 51,509 | 63,772 | 48,794 | 116,269 | -176,335 | -143,216 | -7,757 | -152,984 | 37,737 | 40,237 | 54,722 | 44,742 | 14,146 |
Cashflow From Financing | 16.4% | 3,004 | 2,581 | 8,585 | 3,640 | 2,187 | 5,654 | 5,504 | 441,814 | 7,914 | 591 | 1,582 | 1,432 | 3,635 | 378,494 | 4,480 | 277,567 | 2,793 | 152 | 259 | 31.00 | 186 |
Consolidated Statements of Operations - USD ($) $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Total revenues, net | $ 464,370 | $ 250,314 | $ 83,803 |
Operating expenses: | |||
Cost of product sales | 33,745 | 20,443 | 8,035 |
Selling, general and administrative | 409,864 | 358,782 | 272,611 |
Research and development | 180,142 | 134,715 | 88,845 |
Total operating expenses | 623,751 | 513,940 | 369,491 |
Loss from operations | (159,381) | (263,626) | (285,688) |
Interest income | 20,343 | 7,376 | 1,568 |
Loss before provision for income taxes | (139,038) | (256,250) | (284,120) |
Income tax expense | (636) | (6) | (6) |
Net loss | $ (139,674) | $ (256,256) | $ (284,126) |
Net loss per common share: | |||
Basic (in dollars per share) | $ (1.46) | $ (2.72) | $ (3.50) |
Diluted (in dollars per share) | $ (1.46) | $ (2.72) | $ (3.50) |
Weighted average number of common shares: | |||
Basic (in shares) | 95,881,729 | 94,046,670 | 81,253,394 |
Diluted (in shares) | 95,881,729 | 94,046,670 | 81,253,394 |
Product sales, net | |||
Total revenues, net | $ 462,175 | $ 249,132 | $ 81,708 |
Grant revenue | |||
Total revenues, net | $ 2,195 | $ 1,182 | $ 2,095 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 147,767 | $ 148,615 |
Investment securities, available-for-sale | 350,174 | 443,290 |
Restricted cash | 1,750 | 1,750 |
Accounts receivable, net | 114,018 | 75,189 |
Inventory | 11,647 | 23,920 |
Prepaid expenses and other current assets | 42,443 | 45,193 |
Total current assets | 667,799 | 737,957 |
Property and equipment, net | 1,654 | 1,913 |
Right of use assets, net | 12,928 | 14,824 |
Inventory, non-current | 38,621 | 0 |
Other assets | 7,293 | 86 |
Total assets | 728,295 | 754,780 |
Current liabilities: | ||
Accounts payable | 11,452 | 10,395 |
Accrued and other current liabilities | 27,944 | 19,657 |
Accrued customer programs | 53,173 | 25,621 |
Accrued employee benefits | 27,364 | 22,996 |
Operating lease liabilities | 3,612 | 4,567 |
Total current liabilities | 123,545 | 83,236 |
Operating lease liabilities, non-current | 13,326 | 15,474 |
Total liabilities | 136,871 | 98,710 |
Stockholders’ equity: | ||
Common stock, $0.0001 par value: 175,000,000 shares authorized at December 31, 2023 and December 31, 2022, respectively; 96,379,811 and 94,829,794 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively | 10 | 9 |
Additional paid-in capital | 2,208,470 | 2,137,737 |
Accumulated deficit | (1,617,160) | (1,477,486) |
Accumulated comprehensive income (loss) | 104 | (4,190) |
Total stockholders’ equity | 591,424 | 656,070 |
Total liabilities and stockholders’ equity | $ 728,295 | $ 754,780 |
 | Dr. Sharon Mates Ph.D. |
---|---|
 | intracellulartherapies.com |
 | Pharmaceuticals |
 | 561 |